Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (apre una nuova finestra)

Barillari G, Pasca S, Barillari A, De Angelis V.

Fonte‎: Blood Transfus 2012;10(1):87-94.

Indicizzato‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (apre una nuova finestra)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (apre una nuova finestra)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Fonte‎: Chest 2012;141(2 Suppl):e326S-50S.

Indicizzato‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (apre una nuova finestra)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (apre una nuova finestra)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Fonte‎: Lancet 2015;385(9982):2077-87.

Indicizzato‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (apre una nuova finestra)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (apre una nuova finestra)

Hanke AA, Joch C, Görlinger K.

Fonte‎: Br J Anaesth 2013;110(5):764-72.

Indicizzato‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (apre una nuova finestra)

Emergency reversal of warfarin anticoagulation. (apre una nuova finestra)

Lin Y, Callum J.

Fonte‎: CMAJ 2010;182(18):2004.

Indicizzato‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (apre una nuova finestra)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (apre una nuova finestra)

Mo Y, Yam FK.

Fonte‎: Pharmacotherapy 2015;35(2):198-207.

Indicizzato‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (apre una nuova finestra)

Idarucizumab for dabigatran reversal - full cohort analysis. (apre una nuova finestra)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Fonte‎: N Engl J Med 2017;377(5):431-41.

Indicizzato‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (apre una nuova finestra)

Oral anticoagulation in surgical procedures: risks and recommendations. (apre una nuova finestra)

Torn M, Rosendaal FR.

Fonte‎: Br J Haematol 2003;123(4):676-82.

Indicizzato‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (apre una nuova finestra)